Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Regulatory News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,510.00
Bid: 12,524.00
Ask: 12,526.00
Change: 118.00 (0.95%)
Spread: 2.00 (0.016%)
Open: 12,468.00
High: 12,556.00
Low: 12,434.00
Prev. Close: 12,392.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Replacement - Form 8 (OPD) (Pfizer)

21 May 2014 11:49

RNS Number : 6933H
Pfizer Inc
21 May 2014
 

FORM 8 (OPD)

 

PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER

Rules 8.1 and 8.2 of the Takeover Code (the "Code")

 

AMENDMENT - CHANGES TO SECTION 3.2

 

1. KEY INFORMATION

 

(a) Identity of the party to the offer making the disclosure:

Pfizer Inc. ("Pfizer")

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

N/A

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

AstraZeneca PLC

(d) Is the party to the offer making the disclosure the offeror or the offeree?

Offeror

(e) Date position held:

9 May 2014

(f) Has the party previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?

Yes, Pfizer Inc.

 

2. POSITIONS OF THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates

 

Class of relevant security:

 

Ordinary Shares

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

Nil

Nil

(2) Derivatives (other than options):

Nil

Nil

(3) Options and agreements to purchase/sell:

Nil

Nil

 

TOTAL:

Nil

Nil

 

 

(b) Rights to subscribe for new securities

 

Class of relevant security in relation to which subscription right exists:

None

Details, including nature of the rights concerned and relevant percentages:

N/A

 

 

(c) Irrevocable commitments and letters of intent

 

Details of any irrevocable commitments or letters of intent procured by the party to the offer making the disclosure or any person acting in concert with it (see Note 3 on Rule 2.11 of the Code):

 

None.

 

 

3. POSITIONS OF PERSONS ACTING IN CONCERT WITH THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

Details of any interests, short positions and rights to subscribe of any person acting in concert with the party to the offer making the disclosure:

 

See below

 

 

3.1 Pfizer Directors

 

Name of Director

Number of Ordinary Shares[1] held

Percentage of total issued ordinary shares (excluding treasury shares)

Stephen W. Sanger

161

0.00%

 

 

3.2 Advisers to Pfizer [2]

 

J.P. Morgan (J.P. Morgan Securities plc and J.P. Morgan Trust Company of Delaware)

 

Class of relevant security:

 

Ordinary Shares

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

52,606

0.00%

Nil

(2) Derivatives (other than options):

Nil

Nil

(3) Options and agreements to purchase/sell:

Nil

Nil

 

TOTAL:

52,606

0.00%

Nil

 

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the party to the offer making the disclosure or any person acting in concert with it:

 

None.

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the party to the offer making the disclosure, or any person acting in concert with it, and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

 

None.

 

 

(c) Attachments

 

Are any Supplemental Forms attached?

 

Supplemental Form 8 (Open Positions)

No

Supplemental Form 8 (SBL)

No

 

 

Date of disclosure:

12 May 2014

Contact name:

Chris Dickinson

Geoff Iles

Telephone number:

+44 (0) 207 134 7302

+44 (0) 207 995 1930

 


[1] Comprises AstraZeneca ordinary shares held by Stephen W. Sanger 's close relatives, whether directly or in trust (to his knowledge after inquiry).

[2] The information in this section was provided to Pfizer by the relevant adviser

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FEEBFLFLZEFZBBL
Date   Source Headline
11th Sep 20177:00 amRNSTagrisso potential standard of care in lung cancer
11th Sep 20177:00 amRNSIMFINZI superior PFS in Stage III lung cancer
7th Sep 201712:39 pmRNSCelgene and AZ update on Fusion trial programme
7th Sep 20177:00 amRNSAZ Duaklir improves lung function in COPD patients
7th Sep 20177:00 amRNSAZ tezepelumab cuts exacerbations in severe asthma
5th Sep 20177:00 amRNSDirectorate Change
1st Sep 20173:00 pmRNSTotal Voting Rights
29th Aug 20177:00 amRNSFaslodex gets US FDA OK for expanded use in breast
18th Aug 20177:00 amRNSLynparza gets broad FDA approval in ovarian cancer
16th Aug 20177:00 amRNSDirectorate Change
14th Aug 20174:30 pmRNSHolding(s) in Company
10th Aug 20171:30 pmRNSPublication of a Prospectus
2nd Aug 20177:00 amRNSAZ acalabrutinib submission accepted by US FDA
1st Aug 20173:00 pmRNSTotal Voting Rights
1st Aug 20177:00 amRNSBTD for AZ's acalabrutinib in mantle cell lymphoma
31st Jul 20177:00 amRNSImfinzi granted BTD by US FDA for Stage III nsclc
28th Jul 201711:00 amRNSDirector/PDMR Shareholding
27th Jul 20177:15 amRNSTagrisso significantly improves FLAURA
27th Jul 20177:11 amRNSAZ reports initial results from MYSTIC lung trial
27th Jul 20177:06 amRNSAZ & MERCK ESTABLISH STRATEGIC ONCOLOGY DEAL
27th Jul 20177:00 amRNSAstraZeneca PLC - H1 2017 Results
26th Jul 20174:46 pmRNSFaslodex receives EU approval for 1L breast cancer
21st Jul 20173:45 pmRNSHolding(s) in Company
3rd Jul 20172:59 pmRNSTotal Voting Rights
3rd Jul 20177:00 amRNSAZ COMPLETES SELOKEN AGREEMENT WITH RECORDATI
3rd Jul 20177:00 amRNSAZ COMPLETES ZOMIG DIVESTMENT WITH GRÜNENTHAL
23rd Jun 201712:46 pmRNSFaslodex CHMP positive opinion in 1L breast cancer
7th Jun 20177:13 amRNSAZ agreement with Grünenthal for rights to Zomig
6th Jun 20177:00 amRNSASTRAZENECA PRICES A $2BN BOND ISSUE
5th Jun 20177:00 amRNSLYNPARZA: SIGNIFICANT PFS IN BRCAm BREAST CANCER
1st Jun 20173:00 pmRNSBlock listing Interim Review
1st Jun 20173:00 pmRNSTotal Voting Rights
31st May 20177:00 amRNSDirectorate Change
24th May 20173:00 pmRNSDirector/PDMR Shareholding
23rd May 20177:00 amRNSBydureon EXSCEL trial meets T2D safety objective
22nd May 20177:00 amRNSAZ AGREEMENT WITH RECORDATI FOR SELOKEN IN EUROPE
16th May 20173:00 pmRNSDirector/PDMR Shareholding
12th May 20177:00 amRNSIMFINZI SIGNIFICANT PFS - UNRESECTABLE LUNG CANCER
10th May 20177:00 amRNSAZ updates on tralokinumab trial in severe asthma
2nd May 20172:00 pmRNSTotal Voting Rights
2nd May 20177:00 amRNSDURVALUMAB RECEIVES US FDA ACCELERATED APPROVAL
27th Apr 20175:30 pmRNSResult of AGM
27th Apr 20177:00 amRNSAstraZeneca: Q1 2017 Results
25th Apr 20171:30 pmRNSTAGRISSO RECEIVES FULL APPROVAL IN THE EU
12th Apr 20175:34 pmRNSNotification of Major Interest in Shares
3rd Apr 20173:00 pmRNSTotal Voting Rights
31st Mar 20177:01 amRNSTagrisso (osimertinib) receives FDA full approval
31st Mar 20177:00 amRNSAZ COMPLETES AGREEMENT WITH TERSERA THERAPEUTICS
28th Mar 20174:00 pmRNSDirector/PDMR Shareholding
27th Mar 20173:00 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.